We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
- Authors
Berenson, James R.; Yellin, Ori; Woytowitz, Donald; Flam, Marshall S.; Cartmell, Alan; Patel, Ravi; Duvivier, Herb; Nassir, Youram; Eades, Benjamin; Abaya, Christina DiLauro; Hilger, Jacqueline; Swift, Regina A.
- Abstract
Background: We conducted a single-arm, multicentre phase 2 study to evaluate bortezomib, ascorbic acid and melphalan (BAM) for patients with newly diagnosed multiple myeloma (MM). Methods: Induction consisted of up to eight 28-d cycles of bortezomib 1.0 mg/m2 on days 1, 4, 8 and 11, plus oral ascorbic acid 1 g and oral melphalan 0.1 mg/kg on days 1–4, followed by maintenance bortezomib 1.3 mg/m2 every 2 wk until progression. Results: Among 35 patients enrolled (median age 70 yr), responses occurred in 23/31 evaluable patients (74%) including five (16%) complete, three (10%) very good partial, six (19%) partial and nine (29%) minimal responses. Six patients (19%) had stable disease. Thus, disease control was achieved in 29 (94%) patients. Median times to first and best responses were 2 and 3 months (ranges 1–5 and 1–7), respectively. Median time to progression was 19 months and median overall survival has not been reached (range 2–23+ months). Grade 3 and 4 adverse events occurred in 17 and 5 patients, respectively; the most common were neutropenia, neuropathy and thrombocytopenia. Conclusions: BAM is an efficacious, well-tolerated and steroid- and immunomodulatory drug (IMiD)-free frontline treatment regimen for MM patients.
- Subjects
VITAMIN C; HEALTH of patients; ALTERNATIVE medicine; BLOOD platelet disorders; NEUROPATHY; IMMUNOREGULATION
- Publication
European Journal of Haematology, 2009, Vol 82, Issue 6, p433
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/j.1600-0609.2009.01244.x